Retatrutide

Retatrutide (LY3437943) is an investigational peptide-based medicine being developed for the treatment of obesity and other metabolic conditions. It is designed as a triple hormone receptor agonist, activating the GLP-1, GIP and glucagon receptors.

By targeting these three pathways simultaneously, retatrutide is being studied for its potential effects on appetite regulation, energy expenditure, glucose metabolism and body-weight reduction. Clinical research has reported substantial reductions in body weight, generating significant interest in retatrutide as a potential future treatment for obesity and related metabolic disorders.

Retatrutide is administered as a once-weekly subcutaneous injection in clinical studies